Moleculin Biotech (NASDAQ:MBRX) Releases Earnings Results, Misses Estimates By $0.72 EPS

Moleculin Biotech (NASDAQ:MBRX) announced its earnings results on Friday. The company reported ($9.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($8.87) by ($0.72), FiscalAI reports.

Moleculin Biotech Trading Down 2.4%

NASDAQ:MBRX traded down $0.19 during mid-day trading on Friday, reaching $7.87. 9,899 shares of the stock were exchanged, compared to its average volume of 33,123. The business has a fifty day moving average price of $10.05 and a 200 day moving average price of $37.12. The firm has a market capitalization of $8.11 million, a PE ratio of -0.06 and a beta of 2.11. Moleculin Biotech has a 1-year low of $3.23 and a 1-year high of $229.40.

Analyst Upgrades and Downgrades

A number of research firms have commented on MBRX. HC Wainwright dropped their price target on shares of Moleculin Biotech to $60.00 and set a “buy” rating on the stock in a research report on Friday, August 28th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Thursday, October 15th. Finally, Wall Street Zen lowered shares of Moleculin Biotech from a “sell” rating to a “strong sell” rating in a research note on Saturday, November 7th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Moleculin Biotech presently has an average rating of “Hold” and a consensus price target of $60.00.

About Moleculin Biotech

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for cancers and other serious diseases. The company uses its proprietary technology platforms to design drug candidates intended to address treatment resistance, improve drug delivery, and target biological pathways involved in disease progression. Moleculin’s lead program is Annamycin, a liposomal formulation of the anthracycline doxorubicin being investigated for acute myeloid leukemia and soft-tissue sarcoma.